NCT07161388 (DREAM) is a clinical trial in Limited Stage Small-Cell Lung Cancer, sponsored by AstraZeneca.

Who is sponsoring NCT07161388?

NCT07161388 is sponsored by AstraZeneca.

What condition does NCT07161388 study?

NCT07161388 studies Limited Stage Small-Cell Lung Cancer.

Is NCT07161388 still recruiting?

NCT07161388 is currently recruiting now. Last updated 2 April 2026.

Last reviewed 2026-04-02 · How we verify

NCT07161388: DREAM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China

Recruiting now Last updated 2 April 2026

What this trial tests

trial in Limited Stage Small-Cell Lung Cancer in 200 participants. Currently enrolling.

Timeline

17 November 2025

Primary endpoint
30 September 2028

30 September 2028

Quick facts

Lead sponsor	AstraZeneca
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	200
Start date	17 November 2025
Primary completion	30 September 2028
Estimated completion	30 September 2028
Sites	24 locations across China

Conditions studied

Limited Stage Small-Cell Lung Cancer — all drugs for Limited Stage Small-Cell Lung Cancer →

Sponsor

AstraZeneca — full company profile →

Who can join

18 and older, any sex, with Limited Stage Small-Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This prospective, multicentre, observational study aims to assess the effectiveness and safety of durvalumab as consolidation treatment for patients with LS-SCLC who have not progressed following CRT in real-world setting.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07161388 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 2 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07161388.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing